No Benefit of Long-Acting Antipsychotics in Schizophrenia?

New research questions whether long-acting injectable antipsychotics are better than oral medications in preventing treatment discontinuation in early-phase schizophrenia.

Related Keywords

Israel ,Germany ,New York ,United States ,Netherlands ,United Kingdom ,University Hospital ,Long Island ,London ,City Of ,Dainippon Sumitomo ,Martina Hahn ,John Kane ,King College London ,Alkermes ,Vanguard Research Group ,Boehringer Ingelheim ,Department Of Psychiatry ,Goethe University ,Institute Of Behavioral Science ,Health Rhythms ,Department Of Mental Health ,Lundbeck ,Feinstein Institutes For Medical Research ,Inge Winter Van Rossum ,Mount Sinai ,New York City ,College London ,Medscape Medical News ,Behavioral Science ,Feinstein Institutes ,Medical Research ,Barbara Zucker School ,University Hospital Goethe ,Sibylle Christine Roll ,Mental Health ,Varisano Hospital ,Winter Van Rossum ,Intracellular Therapies ,North Shore Therapeutics ,Published January ,Schizophrenia ,Antipsychotics ,Neuroleptics ,Neuroleptic Drugs ,Hospitals ,Patient Safety ,Drug Interactions ,Inpatient Services ,Adverse Effects ,Side Effects ,Europe ,European ,Inpatient Care ,Preventive Screening ,Screening ,Psychotherapy ,Remission ,Therapeutic Drug Monitoring ,United Kingdom Site Content ,Atypical Antipsychotics ,